About COMPASS Pathways

COMPASS Pathways is a UK-based biopharmaceutical company developing COMP360 — a synthetic, standardized psilocybin — for treatment-resistant depression. Having completed a significant Phase 2b trial showing dose-dependent effects, COMPASS is advancing toward Phase 3 clinical trials. It represents the largest corporate investment in psilocybin therapy development globally and is the leading candidate for eventual FDA approval of a psilocybin-based treatment.

Location & Legal Context

COMPASS Pathways operates in United Kingdom. Before visiting or purchasing, review the psilocybin laws in United Kingdom to understand the current legal landscape.

Community Reviews

Community reviews coming in Phase 2. Have you worked with COMPASS Pathways? Share your experience in the forum.

LearnShrooms lists vendors for informational purposes. Verify legality in your jurisdiction before purchasing. Vendors are responsible for their own legal compliance. Check United Kingdom laws →